Xeris Biopharma Holdings Inc (NAS:XERS)
$ 1.975 -0.035 (-1.74%) Market Cap: 292.81 Mil Enterprise Value: 479.34 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Q4 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript

Mar 06, 2024 / 01:30PM GMT
Release Date Price: $2.48 (-19.48%)
Operator

Hello, everyone, and welcome to the Xeris Fourth Quarter and Full Year 2023 financial results conference call and webcast. My name is Emily, and I'll be coordinating your call today. (Operator Instructions)

I'll now turn the call over to Allison Wey, Senior Vice President of Investor Relations. Please go ahead.

Allison Wey
Xeris Biopharma Holdings, Inc. - SVP of IR & Corporate Communications

Thank you, Emily. Good morning and welcome to Xeris Biopharma's Fourth Quarter and Full Year 2023 financial results and conference call. This morning, we issued two press releases, one on the Company's financial results and the other on refinancing. Our debt facilities with paper and capital flows can be found on our website.

We're joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, our CFO. After our prepared remarks, we will open the lines for questions.

Before we begin, I would like to remind you that this call will contain certain forward-looking statements concerning the Company's future expectations, plans,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot